May 2, 2019
Veeva, Cvent integrate Best-in-Class Events Management Capabilities
Industry leaders partner to help life sciences companies compliantlymanage global events
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 1, 2019
Optivida Health, Frelii in deal for DNA sequencing services
Optivida will leverage Frelii’s proprietary DNAKit Packages™ to ensure Optivida customers can realize the optimalbenefits of which specific Optivida products best suit their unique DNAprofile.
May 1, 2019
1-Day Seminar: Drafting & Negotiating Clinical Trial Agreements
Clinical trial agreements are one of the most important agreements inthe pharma industry as no research can start without the right agreementin place between sponsor and host organisation.
May 1, 2019
Noble launches its YpsoMate training device platform, elevates patient access
Noble unveiled today a new injectiontraining platform based on 1 mL and 2.25 mL YpsoMate devices to helpimprove patient onboarding and health outcomes.
May 1, 2019
Dr. James Summers appointed to Mission Therapeutics’ board of directors
Mission Therapeutics today announced the appointment of Dr. James Summers asan independent member to its Board of Directors, with immediate effect.
April 30, 2019
Vertex total product revenues increased 34%,driven by SYMDEKO in the U.S. in first-quarter 2019
– First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018- – First-quarter 2019…
April 30, 2019
Sinovant Sciences net approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration
Chinese registrational clinical trial for derazantinib to begin in 2H 2019 BURLINGTON, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24ARQL&src=ctag” target=”_blank”gt;$ARQLlt;/agt; lt;a href=”https://twitter.com/hashtag/arql?src=hash” target=”_blank”gt;#arqllt;/agt;–ArQule, Inc.’s…
April 30, 2019
Alnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran)
− In the United States, Company Completes Tenth Value-Based Agreement with Commercial Payers, and Achieves Confirmed Access to ONPATTRO for…
April 30, 2019
FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age
-Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support…
April 30, 2019
CORRECTING and REPLACING Sproutly Announces Joint Venture with Moosehead Breweries to Launch Cannabis-Infused Beverages in Canada
NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICES VANCOUVER, British Columbia–(BUSINESS WIRE)–Date of conference call should read:…